Mykronor (Noradrenaline Tartrate)

Noradrenaline tartrate, the active ingredient in Mykronor, is a sympathomimetic agent presented as an injectable solution for intravenous use. It acts as a potent vasopressor, raising blood pressure by causing vasoconstriction and supporting cardiac output, and is employed in acute hypotension, septic shock, cardiogenic shock and cardiac arrest in critical care settings.

GNH USA supplies Mykronor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, providing reliable sourcing for critical care medicines through established distribution networks.

Mykronor is a vasopressor used in critical care to restore circulatory stability in severe hypotensive states.

Acute hypotension: raises systemic vascular resistance to maintain organ perfusion. Septic shock: improves blood pressure when fluid resuscitation alone is insufficient. Cardiogenic shock: supports cardiac output and arterial pressure during heart failure. Cardiac arrest: provides immediate pressor support during resuscitation efforts.

Mykronor may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Tachycardia: increased heart rate due to beta‑1 stimulation. - Headache: vascular changes can provoke cranial discomfort. - Nausea: gastrointestinal upset may occur. - Peripheral ischemia: reduced blood flow to extremities.

Serious or Rare Side Effects: - Severe hypertension: excessive blood pressure rise. - Myocardial ischemia: reduced coronary perfusion leading to chest pain. - Tissue necrosis at injection site: local vascular compromise. - Anaphylaxis: rare severe allergic reaction.

When using Mykronor, clinicians should observe specific precautions to minimize risks and ensure safe administration. - Cardiac monitoring: continuous ECG and blood pressure monitoring is required. - Dose titration: adjust infusion rate based on hemodynamic response. - Contraindications: avoid in patients with uncorrected hypovolemia. - Drug interactions: be aware of synergistic effects with other vasopressors. - Pregnancy and lactation: use only if benefits outweigh potential risks, as safety data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mykronor can interact with other agents, influencing its pressor effect or causing adverse events.

Major Interactions (Avoid): - Phosphodiesterase inhibitors (e.g., milrinone): may cause profound hypotension. - Beta‑blockers: can blunt the beta‑1 mediated increase in cardiac output. - MAO inhibitors: increase risk of hypertensive crisis.

Moderate Interactions (Monitor Closely): - Other vasopressors (e.g., dopamine): may lead to excessive vasoconstriction. - Calcium channel blockers: may enhance vasoconstrictive effects. - Sedatives and anesthetics: may mask signs of hypertension.